A Canada based past client of Aagami, has appointed Aagami for seeking licensing/do-development partnerships for their Phase 3 chemotherapy candidate, in South Korea, Taiwan, Turkey, Austalia and New Zealand.

The client is focused on the development and commercialization of new cancer therapies. Their lead product candidate, is a “first-in-class” small molecule chemotherapy that has recently completed a Phase 2 clinical trial (in US) for the treatment of refractory GlioBlastoma Multiforme (GBM), the most common and aggressive form of brain cancer.
The client company is also exploring its candidate as a therapy for front-line GBM and solid tumors including NSCLC and ovarian cancer.

Aagami looks forward to bringing success to its client and establishing meaningful partnerships. Aagami CEO will also be meeting prospective companies during his visit to South Korea in December 2016.